HRT, UPDATE 2009 Progestinici e nuove associazioni
|
|
- Marshall Hines
- 5 years ago
- Views:
Transcription
1 HRT, UPDATE 2009 Progestinici e nuove associazioni Marco Gambacciani Executive Board International Menopause School Executive Board European Menopause and Andropause Society Menopause and Osteoporosis Unit Pisa University Hospital, Italy Research Support, Grants and Occasional Honoraria: Bracco, Eli Lilly&Company, Igea, Lunar Corporation, MS&D, Novartis, Novo Nordisk, Organon, Pfizer, P&G, Schering, Solvay, Wyeth.
2 The International Menopause Society The IMS Updated Recommendations on postmenopausal hormone therapy February 27, 2007 Climacteric 2007;10:181 94
3 ULTIMATE HRT EFFECTS PATIENT SELECTION TIMING OF INTERVENTION TYPE AND DOSES OF HORMONES
4 Classification of synthetic progestogens Progestogens C-21 progestogens C-19 nortestosterone Spirolactone Pregnanes Estranes Gonanes Drospirenone Medroxyprogesterone acetate Megestrol acetate Cyproterone acetate Dehydrogesterone Norethindrone Noreth. acetate Ethynodiol diacetate Lynestrenol Norethynodrel Norgestrel Levonorgestrel Norgestimate Desogestrel Gestodene Dienogest
5 Comparison of drospirenone with other progestins Progestogenic activity Androgenic activity Antiandrogenic activity Antialdosterone activity Glucocorticoid activity P4 + (+) + DRSP CPA + + (+) DSG + (+) GD + (+) (+) LNG + (+) NGM + (+) MPA + (+) (+) NETA + (+) + relevant activity; (+) activity not clinically relevant; no activity CPA: cyproterone acetate; DSG: desogestrel; GD: Gestoden; LNG: levonorgestrel; NGM: norgestimate; MPA: medroxy progesterone acetate; NETA: noretisterone acetate Schindler AE et al. Maturitas. 2003;46(suppl 1):S7-S16; Rübig A. Climacteric. 2003;6(suppl 3):49-54.
6 Invasive Breast Cancer 0,03 Cumulati ive Hazard 0,02 0,01 Placebo CEE + MPA HR % CI Time, y WHI, JAMA 2002
7 Effects of CEE on Breast Cancer and Mammography Screening in Postmenopausal Women With Hysterectomy Stefanick et al., JAMA. 2006;295:
8 Combined hormone replacement therapy and risk of breast cancer a French cohort study including 3175 PMW followed for a mean of 8.9 years ( woman-years) (55%) of these women were users of one type of estrogen replacement with systemic effect during at least 12 months, any time after the menopause, and were classified as HRT users. Among them, 83% were receiving exclusively or mostly a combination of a transdermal estradiol gel and a progestin other than MPA. 105 cases of breast cancer occurred during the follow-up period, corresponding to a mean of 37 new cases per women/year. 2 1,5 control HRT RR 0.98, 95% confidence interval (CI): RR 1 0,5 0 B. de Lignières et al., Climacteric, 2002; 5:
9 E3N-EPIC EPIC French cohort study postmenopausal women (teachers) HRT users versus non users Mean age at inclusion 52.8 yrs Mean follow up: 5.8 yrs HRT use (mean duration 2.8 yrs) Breast cancer RR 95%C.I. Ever E alone E+P syntetic P micronized P Fournier, Int J Cancer 2005
10 progestins and breast cancer Effects of P4 and progestins alkaline phosphatase enzymatic activity in T47Dco cells. Bray et al, Journal of Steroid Biochemistry & Molecular Biology, 2005
11 progestins and breast cancer Number of genes regulated by progestin treatment in T47D breast cancer cells The bars represent the results of three independent and time-separated experiments. The number of up-regulated (white bars) and down-regulated (black bars) genes are indicated. Bray et al, Journal of Steroid Biochemistry & Molecular Biology, 2005
12 Comparative effects of different progestin on the activation of the actin-regulatory protein, moesin BMC Cancer. 2008; 8: 166.
13 Progestins alone or in combination with E2 promote T47-D breast cancer cell invasion. * = P < 0.01 vs. control; # = P < 0.05 vs. E2. BMC Cancer. 2008; 8: 166.
14 PROGESTOGEN MAKES THE DIFFERENCE DROSPIRENONE The Unique Progestogen Progesterone effects Endometrial safety Cycle control Antimineralocorticoid activity Progesterone-like effects on sodium and water retention breast tension edema body weight Some premenstrual symptoms CVD risk (?) Antiandrogenic activity Blockage of androgen receptor acne seborrhea Progestogen with Aldosterone Receptor Antagonism (PARA)
15 Renin-angiotensin-aldosterone system (RAAS) Angiotensin I + Renin substrate (angiotensinogen) Estrogen Renin - Increased plasma volume - Increased blood pressure in susceptibles - Water retention-related symptoms (edema, bloating, weight gain, breast tension) Angiotensin II Na + /water retention K + elimination Drospirenone Progesterone Aldosterone
16 Different estrogens have different dose-related effects on angiotensinogen % of ba aseline β-E 1 mg 17β-E 2 mg EV 2 mg 17β-E TD 50 µg EV = estradiol valerate; TD = transdermal Adapted from Lippert TH et al. Sex Steroids and the Cardiovascular System. Carnforth, UK, Parthenon, 1998:201 10
17 RAAS Plays a Central Role in Organ Damage A II Aldosterone Atherosclerosis* Vasoconstriction Vascular hypertrophy Endothelial dysfunction LV hypertrophy Fibrosis Remodeling Apoptosis Stroke Hypertension Heart failure MI DEATH GFR Proteinuria Aldosterone release Glomerular sclerosis *preclinical data LV = left ventricular; MI = myocardial infarction; GFR = glomerular filtration rate Renal failure Adapted from Willenheimer R et al Eur Heart J 1999; 20(14): ; Dahlöf B J Hum Hypertens 1995; 9(suppl 5): S37 S44; Daugherty A et al J Clin Invest 2000; 105(11): ; Fyhrquist F et al J Hum Hypertens 1995; 9(suppl 5): S19 S24; Booz GW, Baker KM Heart Fail Rev 1998; 3: ; Beers MH, Berkow R, eds. The Merck Manual of Diagnosis and Therapy. 17th ed. Whitehouse Station, NJ: Merck Research Laboratories 1999: ; Anderson S Exp Nephrol 1996; 4(suppl 1): 34 40; Fogo AB Am J Kidney Dis 2000; 35(2):
18 Pharmacological and clinical effects of aldosterone and anti-aldosterone action of DRSP
19 Antimineralocorticoid activity 1000 Relative ef fficiency in rats Spironolactone Progesterone Gestodene DRSP Losert W et al. Drug Res. 1985;35:
20 ALDOSTERONE AND ANTIALDOSTERONE DRUGS Role on Bone Metabolism and Density
21 Loss of bone minerals and strength in rats with aldosteronism isolated rat femurs Chhokar, V. S. et al. Am J Physiol Heart Circ Physiol 287: H2023-H ; doi: /ajpheart
22 Spironolactone Prevents Bone Loss in Women Treated with GnRH Agonist gray bar GnRHa alone white bar GnRHa + FLU;. black bar, GnRHa + SPL; *, P < 0.05 vs. baseline, P < 0,05 vs. GnRHa + SPL. Moghetti, P. et al. J Clin Endocrinol Metab 1999;84:
23 Relationship of Use of Spironolactone to Fractures Fracture Site Cases Controls Crude OR (95% CI) p Value Adjusted OR (95% CI) * p Value Total ( ) ( ) Hip ( ) ( ) Wrist ( ) Vertebral ( ) ( ) Other ( ) ( ) * Adjusted for smoking, body mass index, prevalent fracture, and medication exposures. CI = confidence interval Laura D. Carbone, et al, Am Coll Cardiol, 2008; 52:
24 Relationship of Duration of Use of Spironolactone to Total Fractures (vs. Nonuse) Duration of Spironolactone Use Crude Odds Ratio (95% CI) p Value Adjusted Odds Ratio (95% CI) * p Value <6 months (n = 71) ( ) ( ) >6 months (n = 156) ( ) ( ) * Adjusted for smoking, body mass index, prevalent fracture, and medication exposures. Laura D. Carbone, et al, Am Coll Cardiol, 2008; 52:
25 Spironolactone and bone metabolism important skeletal implications aldosteronism in rats is associated with bone loss and a reduction in bone strength decrease calcium and magnesium excretion increase potassium levels Macdonald HM, New SA, Fraser WD, Campbell MK, Reid DM. Low dietary potassium intakes and high dietary estimates of net endogenous acid production are associated with low bone mineral density in premenopausal women and increased markers of bone resorption in postmenopausal women. Am J Clin Nutr 2005;81: Kitchin B, Morgan SL. Not just calcium and vitamin D: other nutritional considerations in osteoporosis. Curr Rheumatol Rep 2007; 9:85 92.
26 ULTIMATE HRT EFFECTS PATIENT SELECTION TIMING OF INTERVENTION TYPE AND DOSES OF HORMONES
27 Reasons for taking HRT 1023 women consulting the Menopause Centre, University Hospital Santa Chiara, Pisa, Italy, in 2002 Osteoporosis prevention Psychological symptoms Genitourinary symptoms Vasomotor symptoms % of patients Gambacciani M. Endocrine 2004
28 Women s Health Questionnaire The Limouzin-Lamotte formula was used to transfer scores into % 0% = worst QoL; 100% = optimal QoL Change from baseline e in WHQ score (Improveme ent) 10 Estradiol 1 mg * Somatic symptoms Depressed mood Anxiety/ fears Sexual functioning Sleep problems Cognitive difficulties Menstrual problems Angeliq Attractiveness ** Global score *P = versus unopposed estradiol; ** p=0.034 versus unopposed estradiol Modified from Archer D et al. Menopause 2005;12:
29 The International Menopause Society Controversial issues in climacteric medicine III HRT IN CLIMACTERIC AND AGING BRAIN, Pisa March, 2003 Estrogen deprivation and symptomatic postmenopausal women 75% of women report hot flushes (HF) around menopause 25% remain symptomatic for >5 years Not all women will experience HF when they become menopausal HF are not just a symptom In postmenopausal women suffering from HF, the brain sensitivity to estrogen depletion is higher
30 Hot flash correlates with high blood pressure Menopause 2007; 14:
31 Menopausal complaints worsen cardiovascular risk 5523 women aged years, of whom 38 percent reported night sweats and 39 percent hot flashes OR in PMW with HF HTN 1.20 ( ) HyperCh 1.52 ( ) Gast et al., Hypertension ,5 1 1,5 2
32 Impact of High-Normal Blood Pressure on the Risk of CVD Definitions and Classification of Blood Pressure Levels European Society of Hypertension European Society of Cardiology (2003) Category Systolic (mmhg) Diastolic (mmhg) Optimal <120 <80 Normal High normal Grade 1 hypertension (mild) Grade 2 hypertension (moderate) Grade 3 hypertension (severe) Isolated systolic hypertension >180 >110 > Journal of Hypertension 2003, Vol 21 No 6
33 Effect of DRSP in human epicardial primary preadipocytes differentiation Courtesy of M Caprio, GM Rosano UNTREATED DROSPIRENONE 10-6M 40x ALDOSTERONE 10-8 M ALDOSTERONE + DROSPIRENONE
34 Effect of Ovarian Hormone Deficiency on Body Fat Distribution T B % FAT MASS * * * LEGS % FAT MASS * TRUNK % FAT MASS * ARMS % FAT MASS * MONTHS OF OBSERVATION MONTHS OF OBSERVATION Gambacciani et al.: Maturitas 2001 *, p<0.01 vs corresponding basal value
35 American Association of Clinical Endocrinologists meta-analysis of 23 trials HRT does not appear to convey cardiovascular risk to younger women in early menopause younger than 60 years or had gone through the menopause less than 10 years with those in older women HRT may even be beneficial. Physicians may safely counsel women to use estrogen for the relief of menopausal symptoms. Each patient should be evaluated for the severity of her symptoms, her age, and specific risk factors that might impact on her use of HRT American Association of Clinical Endocrinologists
36 New progestogens can minimize progestogenic sideeffects through anti-androgenic and antimineralocorticoid effects, e.g. drospirenone
37 EFFETTI DELLA HRT 1. Inizio della terapia 2. selezione delle pazienti 3. Tipo e dose
38 The use of hormones in early menopause and up to age 60 years has a very minor potential for harm, but may carry substantial benefits. Pines A, et al, for the International Menopause Society. Press statement: Recommendations on postmenopausal hormone therapy, 27 February 2007.
39 A volte l'uomo inciampa nella verità, ma nella maggior parte dei casi, si rialza e continua per la sua strada Sir W. Churchill
40
41
Hypertension and diabetic nephropathy
Hypertension and diabetic nephropathy Elisabeth R. Mathiesen Professor, Chief Physician, Dr sci Dep. Of Endocrinology Rigshospitalet, University of Copenhagen Denmark Hypertension Brain Eye Heart Kidney
More informationHORMONE THERAPY A BALANCED VIEW?? Prof Greta Dreyer
HORMONE THERAPY A BALANCED VIEW?? Prof Greta Dreyer -- PART 1 -- Definitions HRT hormone replacement therapy HT genome therapy ERT estrogen replacement therapy ET estrogen EPT estrogen progesterone therapy
More informationHT: Where do we stand after WHI?
HT: Where do we stand after WHI? Hormone therapy and cardiovascular disease risk Experimental and clinical evidence indicate that hormone therapy (HT) reduces the risk of cardiovascular disease (CVD) Women
More informationPostmenopausal hormone therapy - cardiac disease risks and benefits
Postmenopausal hormone therapy - cardiac disease risks and benefits Tomi S. Mikkola, MD Helsinki University Central Hospital Department of Obstetrics and Gynecology Helsinki, Finland Disclosures Speaker/consulting
More informationNovel Approaches for Recognition and Management of Life Threatening Complications of AKI and CKD: Focus on Acute Cardiorenal Syndromes
Novel Approaches for Recognition and Management of Life Threatening Complications of AKI and CKD: Focus on Acute Cardiorenal Syndromes Peter A. McCullough, MD, MPH Baylor University Medical Center, Dallas
More informationLearning Objectives. Peri menopause. Menopause Overview. Recommendation grading categories
Learning Objectives Identify common symptoms of the menopause transition Understand the risks and benefits of hormone replacement therapy (HRT) Be able to choose an appropriate hormone replacement regimen
More informationEstrogens vs Testosterone for cardiovascular health and longevity
Estrogens vs Testosterone for cardiovascular health and longevity Panagiota Pietri, MD, PhD, FESC Director of Hypertension Unit Athens Medical Center Athens, Greece Women vs Men Is there a difference in
More informationPost-menopausal hormone replacement therapy. Evan Klass, MD May 17, 2018
Post-menopausal hormone replacement therapy Evan Klass, MD May 17, 2018 Are we really still talking about this? Are we really still talking about this? 1960-1975- estrogen prescriptions doubled. Pharma
More informationHormones and Healthy Bones Joint Project of National Osteoporosis Foundation and Association of Reproductive Health Professionals
Hormones and Healthy Bones Joint Project of National Osteoporosis Foundation and Association of Reproductive Health Professionals Literature Review (January 2009) Hormone Therapy for Women Women's Health
More informationEstrogens and progestogens
Estrogens and progestogens Estradiol and Progesterone hormones produced by the gonads are necessary for: conception embryonic maturation development of primary and secondary sexual characteristics at puberty.
More informationHRT in Perimenopausal Women. Dr. Rubina Yasmin Asst. Prof. Medicine Dhaka Dental College
HRT in Perimenopausal Women Dr. Rubina Yasmin Asst. Prof. Medicine Dhaka Dental College 1 This is the Change But the CHANGE is not a disease 2 Introduction With a marked increase in longevity, women now
More informationMenopause management NICE Implementation
Menopause management NICE Implementation Dr Paula Briggs Consultant in Sexual & Reproductive Health Southport and Ormskirk NHS Hospital Trust Why a NICE guideline (NG 23) Media reports about HRT have not
More informationKathryn M. Rexrode, MD, MPH. Assistant Professor. Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School
Update: Hormones and Cardiovascular Disease in Women Kathryn M. Rexrode, MD, MPH Assistant Professor Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School Overview Review
More informationTrudy Bush Lecture: Using Progestins in Clinical Practice. Progestins in Clinical Practice: Outline. NAMS Definitions. FDA Approved Oral Progestins
1 Women's Health 2015: The 23rd Annual Congress FRIDAY, April 17, 2015 Trudy Bush Lecture: Using Progestins in Clinical Practice Commercial Disclosure: I am a consultant on litigation relating to the Mirena
More informationDINE AND LEARN ENDOCRINOLOGY PEARLS. Dr. Priya Manjoo, MD, FRCPC Endocrinology, Victoria, BC
DINE AND LEARN ENDOCRINOLOGY PEARLS Dr. Priya Manjoo, MD, FRCPC Endocrinology, Victoria, BC OUTLINE HRT and CVD HRT and Breast Cancer Osteoporosis When to treat How long to treat for Bisphosphonates BMD
More informationLessons from the WHI HT Trials: Evolving Data that Changed Clinical Practice
Lessons from the WHI HT Trials: Evolving Data that Changed Clinical Practice JoAnn E. Manson, MD, DrPH, FACP Chief, Division of Preventive Medicine Interim Executive Director, Connors Center Brigham and
More informationMenopausal Symptoms. Hormone Therapy Products Available in Canada for the Treatment of. Physician Desk Reference - 3rd Edition
Hormone Therapy Products Available in Canada for the Treatment of Menopausal Symptoms Physician Desk Reference - 3rd Edition A clinical resource provided to you by: The Society of Obstetricians and Gynaecologists
More informationMs. Y. Outline. Updates of SERMs and Estrogen
Ms. Y Updates of SERMs and Estrogen Steven R. Cummings, MD, FACP San Francisco Coordinating Center CPMC Research Institute and UCSF Support from Lilly, Pfizer, Berlex 55 y.o. woman with mild hypertension
More informationEstrogen and progestogen therapy in postmenopausal women
Estrogen and progestogen therapy in postmenopausal women The Practice Committee of the American Society for Reproductive Medicine American Society for Reproductive Medicine, Birmingham, Alabama Hormone
More informationOutline. Estrogens and SERMS The forgotten few! How Does Estrogen Work in Bone? Its Complex!!! 6/14/2013
Outline Estrogens and SERMS The forgotten few! Clifford J Rosen MD rosenc@mmc.org Physiology of Estrogen and estrogen receptors Actions of estrogen on bone BMD, fracture, other off target effects Cohort
More informationHRT & Menopause Where Do We Stand Now?
HRT & Menopause Where Do We Stand Now? Mrs. SY Hussain Consultant Gynaecologist The Holly Private Hospital Spire Roding Hospital The Wellington Hospital Discussion Points Discuss Recommendations made by
More informationOptimal blockade of the Renin- Angiotensin-Aldosterone. in chronic heart failure
Optimal blockade of the Renin- Angiotensin-Aldosterone Aldosterone- (RAA)-System in chronic heart failure Jan Östergren Department of Medicine Karolinska University Hospital Stockholm, Sweden Key Issues
More informationBreast Cancer Risk in Patients Using Hormonal Contraception
Breast Cancer Risk in Patients Using Hormonal Contraception Bradley L. Smith, Pharm.D. Smith.bradley1@mayo.edu Pharmacy Ground Rounds Mayo Clinic Rochester April 3 rd, 2018 2017 MFMER slide-1 Presentation
More informationAppendix: Reference Table of HT Brand Names
Appendix: Reference Table of HT Brand Names This is a full reference table in alphabetical order, of Brand Name drugs used in HT. It is the basis for prescription advice throughout this handbook. Drug
More informationSERMS, Hormone Therapy and Calcitonin
SERMS, Hormone Therapy and Calcitonin Tiffany Kim, MD Clinical Fellow VA Advanced Women s Health UCSF Endocrinology and Metabolism I have nothing to disclose Thanks to Clifford Rosen and Steven Cummings
More informationEfficacy and safety of drospirenone 2 mg/17β-estradiol 1 mg hormone therapy in Korean postmenopausal women
Short Communication Obstet Gynecol Sci 2017;60(2):213-217 https://doi.org/10.5468/ogs.2017.60.2.213 pissn 2287-8572 eissn 2287-8580 Efficacy and safety of drospirenone 2 mg/17β-estradiol 1 mg hormone therapy
More informationOrals,Transdermals, and Other Estrogens in the Perimenopause
Orals,Transdermals, and Other Estrogens in the Perimenopause Cases Denise Black, MD, FRCSC Assistant Professor, Obstetrics, Gynecology and Reproductive Sciences University of Manitoba 6/4/18 197 Faculty/Presenter
More informationWHI Estrogen--Progestin vs. Placebo (Women with intact uterus)
HORMONE REPLACEMENT THERAPY In the historical period it was commonly held that estrogen had two principal benefits to postmenopausal women: 1) To alleviate the constitutional symptoms related to the climacteric
More informationWEIGHING UP THE RISKS OF HRT. Department of Endocrinology Chris Hani Baragwanath Academic Hospital
WEIGHING UP THE RISKS OF HRT V. Nicolaou Department of Endocrinology Chris Hani Baragwanath Academic Hospital Background Issues surrounding post menopausal hormonal therapy (PMHT) are complex given: Increased
More informationManaging menopause in Primary Care and recent advances in HRT
Managing menopause in Primary Care and recent advances in HRT Raj Saha, MD, DMRT, FRCOG Consultant Gynaecologist Heart of England NHS Foundation Trust rajsaha1@yahoo.co.uk Content of today s talk Aims
More informationPractical recommendations for hormone replacement therapy in the peri- and postmenopause
CLIMACTERIC 2004;7:in press Practical recommendations for hormone replacement therapy in the peri- and postmenopause Recommendations from an Expert Workshop, February 2004 Henry Burger, Australia; David
More informationA Fresh Look at ARBs : Focus on HF survival data
A Fresh Look at ARBs : Focus on HF survival data Seok-Min Kang, MD, Ph D. Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea HF specialists ARBs,
More informationEvaluation of the quality of life of postmenopausal women using an estradiol and drospirenone combined oral hormone replacement therapy
HJOG An Obstetrics and Gynecology International Journal Research Evaluation of the quality of life of postmenopausal women using an estradiol and drospirenone combined oral hormone replacement therapy
More informationHormones friend or foe? Undertreatment and quality of life. No conflicts of interest to declare
Hormones friend or foe? Undertreatment and quality of life Anette Tønnes Pedersen MD, Ph.D. Consultant, Associate professor Dept. Of Gynecology / Fertility Clinic Rigshospitalet No conflicts of interest
More informationManaging menopause in Primary Care and recent advances in HRT
Managing menopause in Primary Care and recent advances in HRT Raj Saha, MD, DMRT, FRCOG PG Cert. Advanced Gynaecology Endoscopy Consultant Gynaecologist Heart of England NHS Foundation Trust Spire Parkway
More informationNew products and regimens (since 2003)
CLIMACTERIC 2007;10(Suppl 2):109 114 New products and regimens (since 2003) N. West London Menopause & PMS Centre, London, UK Key words: HORMONE REPLACEMENT THERAPY, ULTRA-LOW-DOSE THERAPY, TRANSDERMAL
More information5. Summary of Data Reported and Evaluation
168 IARC MONOGRAPHS VOLUME 91 5. Summary of Data Reported and Evaluation 5.1 Exposure data The first oral hormonal contraceptives that were found to inhibit both ovulation and implantation were developed
More informationQUERIES: to be answered by AUTHOR
Manuscript Information Climacteric Journal Acronym Volume and issue Author name Manuscript No. (if applicable) DCLI _A_254789 Typeset by KnowledgeWorks Global Ltd. for QUERIES: to be answered by AUTHOR
More informationMenopausal hormone therapy currently has no evidence-based role for
IN PERSPECTIVE HT and CVD Prevention: From Myth to Reality Nanette K. Wenger, M.D. What the studies show, in a nutshell The impact on coronary prevention Alternative solutions Professor of Medicine (Cardiology),
More informationJames H. Liu, M.D. Arthur H. Bill Professor Chair of Reproductive Biology Dept of Obstetrics and Gynecology
Disclosure Estrogen Therapy After Postmenopausal Hysterectomy: Issues, Challenges, Risks/Benefits James H. Liu, M.D. Arthur H. Bill Professor Chair of Reproductive Biology Dept of Obstetrics and Gynecology
More informationManagement of Perimenopausal symptoms
Management of Perimenopausal symptoms Serge Rozenberg CHU St Pierre Université libre de Bruxelles Belgium serge_rozenberg@stpierre-bru.be serge.rozenberg@skynet.be Conflict of interest & Disclosure Conflicts
More informationSex, hormones and the heart
Sex, hormones and the heart Dr Louise Newson BSc(Hons) MBChB(Hons) MRCP FRCGP www.menopausedoctor.co.uk #IandA2017 Declaration I have had financial relationships (lecturer, writer, member of advisory boards
More informationΥπέρταση στις γυναίκες
Υπέρταση στις γυναίκες Ελένη Τριανταφυλλίδη Διευθύντρια ΕΣΥ Καρδιολογίας Υπεύθυνη Αντιυπερτασικού Ιατρείου Β Πανεπιστημιακή Καρδιολογική Κλινική Νοσοκομείο ΑΤΤΙΚΟΝ Cardiovascular disease is the Europe
More informationWomen s Health: Managing Menopause. Jane S. Sillman, MD Assistant Professor of Medicine Harvard Medical School
Women s Health: Managing Menopause Jane S. Sillman, MD Assistant Professor of Medicine Harvard Medical School Disclosures I have no conflicts of interest. Learning Objectives 1. Apply strategies to help
More informationEffects of TX-001HR on Uterine Bleeding Rates in Menopausal Women with Vasomotor Symptoms
Effects of TX-001HR on Uterine Bleeding Rates in Menopausal Women with Vasomotor Symptoms Photo (compulsory) Steven R Goldstein, MD 1 ; Ginger D Constantine, MD 2 ; David F Archer, MD 3 ; James H Pickar,
More informationMenopausal Management: What Has Changed?
Menopausal Management: What Has Changed? Julia V. Johnson, M.D. Professor and Chair, OB/GYN University of Massachusetts Medical School UMass Memorial Medical Center Conflicts of Interest None Learning
More informationUPDATE: Women s Health Issues
UPDATE: Women s Health Issues Renee B. Alexis, MD, MBA, MPH, FACOG Associate Professor Department of OBGYN Kiran C. Patel College of Osteopathic Medicine Disclosure of Conflicts of Interest I have no financial
More informationOB/GYN Update: Menopausal Management What Does The Evidence Show? Rebecca Levy-Gantt D.O. PremierObGyn Napa Inc.
OB/GYN Update: Menopausal Management What Does The Evidence Show? Rebecca Levy-Gantt D.O. PremierObGyn Napa Inc. Napa, California IMPORTANT SAFETY INFORMATION ABOUT EVAMIST: WARNING: ENDOMETRIAL CANCER,
More informationBefore you prescribe
Initiating hormone replacement therapy (HRT) / menopausal hormone therapy (MHT) Dr Sonia Davison Jean Hailes Consultant Endocrinologist Before you prescribe Ensure there are no contraindications to HRT/MHT
More informationControversies in Primary Care Pros and Cons of HRT on patients with CHD
Controversies in Primary Care Pros and Cons of HRT on patients with CHD Claire Bellone MSc Clinical Nurse Specialist Menopause Nottingham Declaration Honorariums & Sponsorship from Bayer, Novonortis, Wyeth
More informationBlood Pressure Measurement (children> 3 yrs)
Blood Pressure Measurement (children> 3 yrs) If initial BP elevated, repeat BP manually 2x and average, then classify Normal BP Systolic and diastolic
More informationDrug Class Review on Estrogens
Drug Class Review on July 2004 Heidi D. Nelson, MD, MPH Peggy Nygren, MA Michele Freeman, MPH Benjamin K. S. Chan, MS Oregon Evidence-based Practice Center Oregon Health & Science University TABLE OF CONTENTS
More informationBSO, HRT, and ERT. No relevant financial disclosures
BSO, HRT, and ERT Jubilee Brown, MD Professor & Associate Director, Gynecologic Oncology Levine Cancer Institute at the Carolinas HealthCare System Charlotte, North Carolina No relevant financial disclosures
More informationThe 6 th Scientific Meeting of the Asia Pacific Menopause Federation
Predicting the menopause The menopause marks the end of ovarian follicular activity and is said to have occurred after 12 months amenorrhoea. The average age of the menopause is between 45 and 60 years
More informationBenton Franklin County Medical Society 31st Annual CME Seminar
Management of Current HT/ET and SERM Recommendations Benton Franklin County Medical Society 31st Annual CME Seminar February 21, 2015 Kennewick, Washington Spokane steoporosis Dr. Lynn Kohlmeier Lynn Kohlmeier,
More informationDisclosures. Learning Objectives. Effects of Hormone Therapy on the Metabolic Syndrome and Cardiovascular Disease. None
Effects of Hormone Therapy on the Metabolic Syndrome and Cardiovascular Disease Micol S. Rothman, MD Associate Professor of Medicine Endocrinology, Diabetes and Metabolism Clinical Director Metabolic Bone
More informationThe 6 th Scientific Meeting of the Asia Pacific Menopause Federation
Delivery of holistic care for the postmenopausal woman Although the average age of menopause is around 50 years, about 10% of women will experience menopause before the age of 45 years, and many women
More informationAntialdosterone treatment in heart failure
Update on the Treatment of Chronic Heart Failure 2012 Antialdosterone treatment in heart failure 전남의대윤현주 Chronic Heart Failure Prognosis of Heart failure Cecil, Text book of Internal Medicine, 22 th edition
More informationA Practitioner s Toolkit for the Management of the Menopause
Medicine, Nursing and Health Sciences A Practitioner s Toolkit for the Management of the Menopause Developed by the Women s Health Research Program School of Public Health and Preventive Medicine Monash
More informationCLINICIAN INTERVIEW CARDIOVASCULAR DISEASE IN POSTMENOPAUSAL WOMEN
CARDIOVASCULAR DISEASE IN POSTMENOPAUSAL WOMEN Nanette K. Wenger, MD, is a recognized authority on women and coronary heart disease. She chaired the US National Heart, Lung, and Blood Institute conference
More informationHormone therapy. Dr. med. Frank Luzuy
Hormone therapy Dr. med. Frank Luzuy Reasons for Initiating/Continuing HT* Menopause-Related Symptoms Osteoporosis, Bone Loss, Fracture Prevention Doctor Prescribed It, Told Me to Take It Cardiovascular
More informationIndian Menopause Society-Goals
Indian Menopause Society-Goals Forum for discussion on all aspects of Menopause and Hormone Therapy To promote Public Awareness Multi disciplinary body Research Promote comprehensive health care for Adult
More informationCoronary Heart Disease in Women Go Red for Women
Coronary Heart Disease in Women Go Red for Women Dr Fiona Stewart Green Lane Cardiovascular Service and National Women s Health Auckland City Hospital Auckland Heart Group Women are Different from Men
More informationMarco Gambacciani President Italian Menopause Society Department of Obstetrics and Gynecology Pisa University Hospital Italy
La Terapia Ormonale Sostitutiva in Menopausa: Rivalutazione dei rischi e benefici nell ultimo decennio Marco Gambacciani President Italian Menopause Society Department of Obstetrics and Gynecology Pisa
More informationPresentation to the Clinical Utility of Treating Patients with Compounded Bioidentical Hormone Therapy
Presentation to the Clinical Utility of Treating Patients with Compounded Bioidentical Hormone Therapy March 5, 2019 Nese Yuksel, BScPharm, PharmD, FCSHP, NCMP Professor Faculty of Pharmacy and Pharmaceutical
More informationDealing with menopausal symptoms in breast cancer patients
Dealing with menopausal symptoms in breast cancer patients Christian Egarter Prof, MD Head: Dept. Gyn. Endocrinology & Reproductive Medicine Medical University of Vienna Disclosure Gideon Richter: Speaker
More informationDrug Class Review on Estrogen for Treatment of Menopausal Symptoms and Prevention of Low Bone Density & Fractures. Final Report
Drug Class Review on Estrogen for Treatment of Menopausal Symptoms and Prevention of Low Bone Density & Fractures Final Report Heidi D. Nelson, MD, MPH Peggy Nygren, MA Benjamin K. S. Chan, MS Produced
More informationNew Insights into Breast Cancer Risk Reduction
New Insights into Breast Cancer Risk Reduction November 10, 2013 Rowan T. Chlebowski Professor of Medicine David Geffen School of Medicine at UCLA Chief, Division of Medical Oncology and Hematology Harbor-UCLA
More information06-Mar-17. Premature menopause. Menopause. Premature menopause. Menstrual cycle oestradiol. Premature menopause. Prevalence ~1% Higher incidence:
Menopause Dr Sonia Davison MBBS FRACP PhD Endocrinologist and Clinical Fellow, Jean Hailes for Women s Health Women s Health Research Program, Monash University = the last natural menstrual period depletion
More information2017 Position Statement of Hormone Therapy of NAMS: overview SHELAGH LARSON, MS, RNC WHNP, NCMP ACCLAIM, JPS HEALTH NETWORK
2017 Position Statement of Hormone Therapy of NAMS: overview SHELAGH LARSON, MS, RNC WHNP, NCMP ACCLAIM, JPS HEALTH NETWORK WHI the only large, long-term RCT of HT in women aged 50 to 79 years, Drug trail
More informationDisclosure Information Relationships Relevant to this Session
Disclosure Information Relationships Relevant to this Session DeCensi, Andrea No relevant relationships to disclose. Please note, all disclosures are reported as submitted to ASCO, and are always available
More informationOVERVIEW OF MENOPAUSE
OVERVIEW OF MENOPAUSE Nicole Budrys, MD, MPH Reproductive Endocrinology Michigan Center for Fertility and Women s Health Presented at SEMCME March 13,2019 Objectives Define menopause Etiology of menopause
More informationSUPPLEMENTAL MATERIAL
SUPPLEMENTAL MATERIAL Supplemental Table 1. Distribution of Participants Characteristics by Treatment Group at Baseline - The Vitamin D and calcium (CaD) Trial of the Women s Health Initiative (WHI) Study,
More informationTURNING DOWN THE HEAT ON MENOPAUSE. Erika Schwartz, M.D.
TURNING DOWN THE HEAT ON MENOPAUSE Erika Schwartz, M.D. www.drerika.com www.bhionline.org U.S. Census Bureau, 2004 US Female Population (000 s) 100000 90000 80000 70000 60000 50000 40000 30000 20000 10000
More informationLow & Ultra Low Dose HRT The Cardiovascular Impact
Low & Ultra Low Dose HRT The Cardiovascular Impact Wyeth Symposium, Turin 29 th Sept 2007 Nick Panay Consultant Gynaecologist Queen Charlotte s & Chelsea and Chelsea & Westminster Hospitals Honorary Senior
More informationStatus Update on the National Cardiovascular Prevention Guidelines - JNC 8, ATP 4, and Obesity 2
TABLE OF CONTENTS Status Update on the National Cardiovascular Prevention Guidelines 1 Drosperinone-Containing Oral Contraceptives and Venous Thromboembolism Risk 1-4 P&T Committee Formulary Action 5 Status
More informationOsteoporosis. When we talk about osteoporosis, we have to be familiar with the constituents of bone and what it is formed of.
Osteoporosis When we talk about osteoporosis, we have to be familiar with the constituents of bone and what it is formed of. Osteoblasts by definition are those cells present in the bone and are involved
More informationMenopause and HRT. John Smiddy and Alistair Ledsam
Menopause and HRT John Smiddy and Alistair Ledsam Menopause The cessation of menstruation Diagnosed retrospectively after 1 year of amenorrhoea Average age 51 in the UK Normal physiology - Menstruation
More informationMisperceptions still exist that cardiovascular disease is not a real problem for women.
Management of Cardiovascular Risk Factors in the Cynthia A., MD University of California, San Diego ARHP 9/19/08 Disclosures Research support Wyeth, Lilly, Organon, Novo Nordisk, Pfizer Consultant fees
More informationDrug Class Review on Hormone Therapy for Postmenopausal Women or Women in the Menopausal Transition Stage
Drug Class Review on Hormone Therapy for Postmenopausal Women or Women in the Menopausal Transition Stage Final Report Update 3 October 2007 Original Report Date: February 2003 Update 1 Report Date: November
More informationVirtual Mentor Ethics Journal of the American Medical Association November 2005, Volume 7, Number 11
Virtual Mentor Ethics Journal of the American Medical Association November 2005, Volume 7, Number 11 Clinical Pearl Post Women's Health Initiative Menopausal Women and Hormone Therapy by JoAnn V. Pinkerton,
More informationPERIMENOPAUSE. Objectives. Disclosure. The Perimenopause Perimenopause Menopause. Definitions of Menopausal Transition: STRAW.
PERIMENOPAUSE Patricia J. Sulak, MD Founder, Living WELL Aware LLC Author, Should I Fire My Doctor? Author, Living WELL Aware: Eleven Essential Elements to Health and Happiness Endowed Professor Texas
More informationOrilissa (elagolix) NEW PRODUCT SLIDESHOW
Orilissa (elagolix) NEW PRODUCT SLIDESHOW Introduction Brand name: Orilissa Generic name: Elagolix Pharmacological class: GnRH antagonist Strength and Formulation: 150mg, 200mg; tabs Manufacturer: AbbVie
More informationHaemostasis, thrombosis risk and hormone replacement therapy
Haemostasis, thrombosis risk and hormone replacement therapy Serge Motte Brussels 13.05.17 - MY TALK TODAY The coagulation cascade and its regulation Effects of hormone replacement therapy on haemostasis
More informationPearls for Menopause Management: I m ready: now what?
Pearls for Menopause Management: I m ready: now what? Friday November 13, 2015 Susan Goldstein MD CCFP FCFP NCMP Assistant Professor Department of Family and Community Medicine University of Toronto Menarche
More informationMenopause & HRT. Rosie & Alex. Image:
Menopause & HRT Rosie & Alex Image: http://www.keepcalm-o-matic.co.uk/ Menopause The permanent cessation of menstruation for 12 months When does it happen? Average age 51 Image: Nature Medicine - 12, 612-613
More informationMENOPAUSE. I have no disclosures 10/11/18 OBJECTIVES WHAT S NEW? WHAT S SAFE?
MENOPAUSE WHAT S NEW? WHAT S SAFE? I have no disclosures Sara Whetstone, MD, MHS OBJECTIVES To describe risks of HT by age and menopause onset To recommend specific HT regimen for women who undergo early
More informationThe preferred treatment for osteoporosis
Alternate Options to Hormone Replacement Therapy for Osteoporosis James R. Shoemaker, DO Andrea B. Klemes, DO This presentation, developed from a symposium lecture at the 40th Annual Convention of the
More informationFemale sex steroids and contraceptives agents
Female sex steroids and contraceptives agents Female Sex Hormones Sex hormones produced by the gonads are necessary for conception, embryonic maturation, and development of primary and secondary sexual
More informationThe Practice Committee of the American Society for Reproductive Medicine,
FERTILITY AND STERILITY VOL. 81, NO. 1, JANUARY 2004 Copyright 2004 American Society for Reproductive Medicine Published by Elsevier Inc. Printed on acid-free paper in U.S.A. PRACTICE COMMITTEE Estrogen
More informationRole of Minerals in Hypertension
Role of Minerals in Hypertension Lecture objectives By the end of the lecture students will be able to Define primary and secondary hypertention and their risk factors. Relate role of minerals with hypertention.
More informationPotential dangers of hormone replacement therapy in women at high risk
ESC meeting, Stockholm, August 30, 16.30-18.00, 2010 Potential dangers of hormone replacement therapy in women at high risk Karin Schenck-Gustafsson MD, PhD, FESC Professor, Chief consultant Department
More informationHormonal Treatment of Acne and Hirsutism. Julie C Harper MD
Hormonal Treatment of Acne and Hirsutism Julie C Harper MD none Conflict of Interest Androgen blockade Decrease androgen production by the gonads or adrenal gland Decrease circulating free testosterone
More informationHRT and bone health. Management of osteoporosis and controversial issues. Delfin A. Tan, MD
Strong Bone Asia V. Osteoporosis in ASEAN (+), Danang, Vietnam, 3 August 2013 Management of osteoporosis and controversial issues HRT and bone health Delfin A. Tan, MD Section of Reproductive Endocrinology
More informationEvaluation and Management of Hypertension in Women. Vesna D. Garovic, M.D. Moscow, Russia, December 2016
Evaluation and Management of Hypertension in Women Vesna D. Garovic, M.D. Moscow, Russia, December 2016 2016 MFMER 3508058-1 Women are not small men There is nothing as powerful as an idea whose time has
More informationTHE RISE AND FALL OF MENOPAUSAL HORMONE THERAPY
Annu. Rev. Public Health 2005. 26:115 40 doi: 10.1146/annurev.publhealth.26.021304.144637 Copyright c 2005 by Annual Reviews. All rights reserved THE RISE AND FALL OF MENOPAUSAL HORMONE THERAPY Elizabeth
More informationPostmenopausal hormone therapy and cancer risk
International Congress Series 1279 (2005) 133 140 www.ics-elsevier.com Postmenopausal hormone therapy and cancer risk P. Kenemans*, R.A. Verstraeten, R.H.M. Verheijen Department of Obstetrics and Gynaecology,
More informationHow HRT Hurts the Heart
How HRT Hurts the Heart Coronary artery disease (CAD) is a killer and recent studies have come up with evidence that HRT might have a role in increasing CAD among women. Why? Zaheer Lakhani, MD, FRCP For
More informationHeart Disease in Women: Is it Really Different?
Heart Disease in Women: Is it Really Different? Jennifer Jarbeau, MD Southcoast Physicians Group Cardiovascular Associates of RI Disclosures I have no financial interests to disclose I wish I did! Are
More information